Maat Pharma SA
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improve… Read more
Maat Pharma SA (MAAT) - Total Liabilities
Latest total liabilities as of June 2025: €40.58 Million EUR
Based on the latest financial reports, Maat Pharma SA (MAAT) has total liabilities worth €40.58 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Maat Pharma SA - Total Liabilities Trend (2017–2024)
This chart illustrates how Maat Pharma SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Maat Pharma SA Competitors by Total Liabilities
The table below lists competitors of Maat Pharma SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bhuwanatala Indah Permai Tbk
JK:BIPP
|
Indonesia | Rp823.54 Billion |
|
ICH Co Ltd
KQ:368600
|
Korea | ₩70.61 Billion |
|
Menif Financial Services Ltd
TA:MNIF
|
Israel | ILA3.16 Billion |
|
Minim Inc
NASDAQ:MINM
|
USA | $861.80K |
|
Destinasi Tirta Nusantara Tbk
JK:PDES
|
Indonesia | Rp216.64 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Maat Pharma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.89 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Maat Pharma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Maat Pharma SA (2017–2024)
The table below shows the annual total liabilities of Maat Pharma SA from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €28.16 Million | +25.37% |
| 2023-12-31 | €22.46 Million | +25.40% |
| 2022-12-31 | €17.91 Million | +87.32% |
| 2021-12-31 | €9.56 Million | +14.69% |
| 2020-12-31 | €8.34 Million | -34.52% |
| 2019-12-31 | €12.73 Million | +175.89% |
| 2018-12-31 | €4.62 Million | +15.57% |
| 2017-12-31 | €3.99 Million | -- |